Brown Advisory Inc. Has $4.27 Million Holdings in Celgene Co. (CELG)

Brown Advisory Inc. reduced its stake in Celgene Co. (NASDAQ:CELG) by 11.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,577 shares of the biopharmaceutical company’s stock after selling 8,241 shares during the period. Brown Advisory Inc.’s holdings in Celgene were worth $4,267,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Janney Capital Management LLC increased its stake in shares of Celgene by 2.9% during the fourth quarter. Janney Capital Management LLC now owns 4,219 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 120 shares during the period. Pitcairn Co. boosted its position in shares of Celgene by 3.0% during the fourth quarter. Pitcairn Co. now owns 4,289 shares of the biopharmaceutical company’s stock valued at $275,000 after purchasing an additional 124 shares in the last quarter. Winthrop Advisory Group LLC boosted its position in shares of Celgene by 4.1% during the fourth quarter. Winthrop Advisory Group LLC now owns 3,171 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 125 shares in the last quarter. Private Trust Co. NA boosted its position in shares of Celgene by 2.2% during the fourth quarter. Private Trust Co. NA now owns 6,245 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 132 shares in the last quarter. Finally, Malaga Cove Capital LLC boosted its position in shares of Celgene by 1.6% during the fourth quarter. Malaga Cove Capital LLC now owns 8,887 shares of the biopharmaceutical company’s stock valued at $566,000 after purchasing an additional 143 shares in the last quarter. 74.19% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently weighed in on CELG shares. Leerink Swann lowered Celgene from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 3rd. BidaskClub upgraded Celgene from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 5th. Robert W. Baird upgraded Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 price target on the stock in a research report on Friday, January 4th. Zacks Investment Research upgraded Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 price target on the stock in a research report on Wednesday, January 23rd. Finally, Canaccord Genuity lowered Celgene from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $100.94.

Celgene stock opened at $88.46 on Friday. The company has a debt-to-equity ratio of 3.21, a quick ratio of 2.12 and a current ratio of 2.23. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $95.30. The firm has a market capitalization of $62.13 billion, a price-to-earnings ratio of 11.62, a P/E/G ratio of 0.39 and a beta of 1.69.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a return on equity of 114.66% and a net margin of 26.48%. The business had revenue of $4.04 billion for the quarter, compared to the consensus estimate of $3.98 billion. During the same period in the previous year, the company posted $2.00 earnings per share. On average, research analysts predict that Celgene Co. will post 10.01 EPS for the current year.

In other Celgene news, Director Ernest Mario purchased 2,000 shares of the stock in a transaction dated Tuesday, February 12th. The shares were purchased at an average cost of $89.99 per share, with a total value of $179,980.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James J. Loughlin sold 23,466 shares of the company’s stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total value of $2,048,347.14. Following the transaction, the director now directly owns 62,102 shares in the company, valued at $5,420,883.58. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2019/03/17/brown-advisory-inc-has-4-27-million-holdings-in-celgene-co-celg.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: What is the Book Value of a Share?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply